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INTRODUCTION
Recent reports disclose the fulminant illness and death of 
a young ophthalmologist named “Li Wenliang” at Wuhan 
Central Hospital in China following exposure with a 
glaucoma patient infected with coronavirus. The 
reportedly healthy ophthalmologist contracted 
coronavirus disease, COVID-19 (2019-nCoV) and 
succumbed a month later following an initially simple red 
eye associated to glaucoma [1]. 
This correspondence highlights a recent alert from the 
American Academy of Ophthalmology (AAO) regarding 
the new potentially pandemic caused by coronavirus 
2019-nCoV and the risks associated to ophthalmic 
practice. Because increasing reports show that 
conjunctivitis may be the first presentation of 
coronavirus infection, triage by ophthalmological services 
may be the first line of transmission of 2019-nCoV as it 
can spread by aerosol contact with conjunctiva [2]. For 
this reason, the AAO and other officials “recommend 
protection for the mouth, nose and eyes when caring 
patients potentially infected with 2019-nCoV”. These 
recommendations include use of an N-95 mask and 
goggles or shield [3]. 
Since its emergence in December 2019, infection caused 
by 2019-nCoV has been characterized as a lower 
respiratory syndrome manifesting as pneumonia and/or 
acute respiratory distress. However, there are still 
considerable gaps in our knowledge of global 
epidemiology of 2019-nCoV, particularly as this infection 
is not confined to a geographical area and does not 
appear to be associated with socioeconomic status; 
however, its seasonal association remains unknown [4]. 
Previous influenza pandemics and outbreaks of other 
deadly infections including Ebola virus, Zika virus, 
chikungunya virus, dengue virus and malaria, have 
elicited an effective response from public health 
agencies, medical doctors and other healthcare 
professionals and both government and non-government 
agencies to control the spread of infection [2]. Today, we 
are facing a new virus demonstrating the ability to spread 
readily from close contact and across continents. 
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As ophthalmic physicians and surgeons, we have the 
scientific, medical and epidemiological knowledge of 
infectious agents causing ocular disease as well as 
systemic infection; adenovirus, and H1N1 are two other 
examples [5, 6]. Patients presenting to ophthalmology 
clinics or to the emergency room with conjunctivitis and 
possessing associated risk factor(s) (travel to high-risk 
areas or contact with persons who have returned from 
such areas or those who are known to be infected) can 
transmit 2019-nCoV infection even before they 
experience other signs and symptoms of infection. In 
other words, we ophthalmologists may be the first line of 
exposure as a newly-infected patient might seek care for 
acute conjunctivitis.  
Like Dr. Li Wenliang, we may be the first to diagnose a 
more serious condition as he did when he notified 
government officials and the public through social media 
after he visited seven patients of possible viral infection 
that presented similar to Severe Acute Respiratory 
Syndrome (SARS) [1]. Therefore, we ophthalmologists 
have an essential role in guiding infection control 
measures to prevent unnecessary exposures to other 
patients, staff and doctors [7]. Recommendations from 
the World Health Organization (WHO) [8], the Centers for 
Disease Control and Prevention (CDC) [2] in the United 
States, and public health agencies from other countries 
regarding standard precaution and safety measures for 
patients and healthcare professionals and protocols for 
limiting risk of spread are an important start against this 
fast-spreading potential pandemic. From previous 
experience with H1N1, pandemics can exert a highly 
disruptive impact on the operations of hospitals and 
outpatient clinics [5].  
Anti-angiotensin-converting enzyme 2 (ACE2) antibody 
have been previously suggested to be able to block the 
coronavirus that causes severe acute respiratory 
syndrome (SARS-COV) replication on Vero E6 cells [9, 10]. 
It has been shown that ACE2 is a crucial SARS-CoV 
receptor in vivo, whereby injection of SARS-CoV Spike 
into mice worsened acute lung failure in vivo, which was 
attenuated by blocking the renin-angiotensin pathway [9, 
10].  
Also, it has been proposed that angiotensin II receptor 
blockers (ARB) is effective in the treatment of viral 
spread of novel coronavirus (Wuhan) [11], but more 
detailed clinical trials are needed to confirm the efficacy 
of different types of ARB on 2019-nCoV to prevent its 
outbreak. 
As ophthalmologists, are we and our medical centers 
prepared to detect acute conjunctivitis due to 2019-
nCoV? Do we have the necessary infrastructure for rapid 
triage, diagnosis, isolation and treatment of patients with 
2019-nCoV? Do we have the necessary personal 
protection equipment to protect ourselves and to 
prevent the spread of infection? In potential pandemic 
emergencies like this one, we ophthalmologists must be 
vigilant, avail ourselves and our staff of task-specific 
education and training regarding prevention of spread, 
and comply with guidelines established by agencies such 
as WHO [8], and CDC [2]. A new chapter is being written 
today in the history of global infectious diseases. It is up 
to us ophthalmologists to assume our role and decide 
how we want to write the next ones. 
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